Palatin Technologies, Inc. Appoints Dr. Anthony M. Manning, Ph.D. to Board of Directors
September 12, 2017 at 07:30 am
Share
Palatin Technologies, Inc. announced that Anthony M. Manning, Ph.D. was appointed to Palatin's Board of Directors on September 7, 2017. Dr. Manning currently serves as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc, Cambridge, MA. Dr. Manning is responsible for research and the discovery of novel products as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc. Since joining Momenta, his team has advanced three novel autoimmune drugs into development. Prior to Momenta, Dr. Manning was Vice President and Head of Immunology Research for Biogen Idec, Inc. Before that, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals.
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Companyâs product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.